Nine-year ocular developmental outcomes after ranibizumab or laser treatment for zone II retinopathy of prematurity: follow-up of a randomized trial cohort.

Lucentis (ranibizumab) - Roche, Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42803828

Guishuang Ying; Guoming Zhang; Jiannan Tang; Laijiao Chen; Mianying Zheng; Xianlu Zeng; Xiayuan Luo; Xinyu Zhao; Yaling Liu; Zhen Yu

Sep 29, 2026